Immunovaccine has reported a net loss of $1.7m for the third quarter ended 30 September 2012 compared to a net loss of $1.5m for the same quarter in 2011. According to the company the increased loss is due to the $155,000 increase in ...
Tags: Net Loss, therapeutic cancer vaccine, immune enhancement technology